NASDAQ:SLS - SELLAS Life Sciences Group Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $18.38
Forecasted Upside: 109.28 %
Number of Analysts: 4
Breakdown:
0 Sell Ratings
0 Hold Ratings
4 Buy Ratings
0 Strong Buy Ratings

^$8.78 As of 07/23/2021 01:00 AM ET

▼ -0.21 (-2.34%)

1 month | 3 months | 12 months

Get New SELLAS Life Sciences Group Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for SLS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLS

^$18.38

▲ +109.28% Upside Potential

This price target is based on 4 analysts offering 12 month price targets for SELLAS Life Sciences Group in the last 3 months. The average price target is $18.38, with a high forecast of $21.00 and a low forecast of $16.50. The average price target represents a 109.28% upside from the last price of $8.78.

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in SELLAS Life Sciences Group.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/1/2020

0 strong buy ratings
1 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/1/2020

0 strong buy ratings
1 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/30/2020

0 strong buy ratings
1 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/28/2020

0 strong buy ratings
1 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/26/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/26/2021

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/25/2021

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/25/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
7/21/2021	Cantor Fitzgerald	Initiated Coverage	Overweight	$18.00	High
6/25/2021	Maxim Group	Boost Price Target	Positive ➝ Buy	$12.00 ➝ $21.00	Medium
6/21/2021	Royal Bank of Canada	Initiated Coverage	Outperform	$18.00	Low
6/3/2021	Alliance Global Partners	Boost Price Target	Buy	$8.00 ➝ $16.50	Medium
5/14/2021	Maxim Group	Reiterated Rating	Buy	$12.00	N/A
2/27/2020	Maxim Group	Reiterated Rating	Buy	$12.00	N/A
11/15/2019	Maxim Group	Upgrade	Hold ➝ Buy		N/A
4/8/2019	Alliance Global Partners	Initiated Coverage	Buy	$225.00	N/A
3/22/2019	Maxim Group	Downgrade	Buy ➝ Hold		N/A
12/6/2018	Maxim Group	Set Price Target	Buy	$250.00	N/A
11/26/2018	Maxim Group	Set Price Target	Buy	$250.00	N/A
11/15/2018	Oppenheimer	Set Price Target	Buy	$650.00	N/A
11/15/2018	Maxim Group	Set Price Target	Buy	$250.00	N/A
11/1/2018	CIBC	Initiated Coverage	Outperform ➝ Outperform		N/A
11/1/2018	Oppenheimer	Initiated Coverage	Outperform	$650.00	N/A
10/22/2018	Maxim Group	Reiterated Rating	Buy	$250.00	N/A
7/31/2018	HC Wainwright	Set Price Target	Buy	$200.00	N/A
7/20/2018	Maxim Group	Lower Price Target	Buy ➝ Buy	$650.00 ➝ $250.00	N/A
6/5/2018	HC Wainwright	Set Price Target	Buy	$550.00	N/A
6/1/2018	Maxim Group	Reiterated Rating	Buy	$650.00	N/A
4/16/2018	Maxim Group	Set Price Target	Buy	$650.00	N/A
4/16/2018	HC Wainwright	Set Price Target	Buy	$550.00	N/A
4/2/2018	HC Wainwright	Reiterated Rating	Buy	$11.00	High
4/2/2018	Maxim Group	Set Price Target	Buy	$650.00	N/A
4/2/2018	HC Wainwright	Initiated Coverage	Buy ➝ Buy	$550.00	N/A
3/19/2018	Maxim Group	Upgrade	Hold ➝ Buy	$650.00	N/A
12/18/2017	Raymond James	Reiterated Rating	Hold		Low
8/9/2017	Maxim Group	Reiterated Rating	Hold		High
2/6/2017	(FBRC)	Downgrade	Outperform ➝ Market Perform	$550.00 ➝ $200.00	N/A
2/2/2017	Maxim Group	Downgrade	Buy ➝ Hold		N/A
1/5/2017	(FBRC)	Reiterated Rating	Outperform	$550.00	N/A
1/3/2017	Maxim Group	Reiterated Rating	Buy	$200.00	N/A
12/4/2016	(FBRC)	Reiterated Rating	Outperform	$550.00	N/A
12/2/2016	Maxim Group	Boost Price Target	Buy	$50.00 ➝ $200.00	N/A
11/11/2016	Maxim Group	Reiterated Rating	Buy	$50.00	N/A
10/23/2016	Maxim Group	Reiterated Rating	Buy	$50.00	N/A
10/13/2016	(FBRC)	Reiterated Rating	Outperform	$100.00	N/A
10/10/2016	Maxim Group	Set Price Target	Buy	$50.00	N/A
9/20/2016	S&P Equity Research	Lower Price Target		$19.50 ➝ $17.00	N/A
8/16/2016	(FBRC)	Reiterated Rating	Outperform	$100.00	N/A
8/10/2016	Maxim Group	Lower Price Target	Buy	$100.00 ➝ $50.00	N/A

(Data available from 7/25/2016 forward)

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company. It engages in the development and commercialization of immunotherapeutic for cancer indications. The firm's product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

Today's Range

Now: $8.78

$8.66

$9.10

50 Day Range

MA: $10.20

$8.29

$13.71

52 Week Range

Now: $8.78

$1.76

$19.38

Volume

205,643 shs

Average Volume

896,255 shs

Market Capitalization

$132.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Frequently Asked Questions

What sell-side analysts currently cover shares of SELLAS Life Sciences Group?

The following sell-side analysts have issued research reports on SELLAS Life Sciences Group in the last year: Alliance Global Partners, Cantor Fitzgerald, Maxim Group, and Royal Bank of Canada.
View the latest analyst ratings for SLS.

What is the current price target for SELLAS Life Sciences Group?

4 Wall Street analysts have set twelve-month price targets for SELLAS Life Sciences Group in the last year. Their average twelve-month price target is $18.38, suggesting a possible upside of 109.3%. Maxim Group has the highest price target set, predicting SLS will reach $21.00 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $16.50 for SELLAS Life Sciences Group in the next year.
View the latest price targets for SLS.

What is the current consensus analyst rating for SELLAS Life Sciences Group?

SELLAS Life Sciences Group currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SLS will outperform the market and that investors should add to their positions of SELLAS Life Sciences Group.
View the latest ratings for SLS.

What other companies compete with SELLAS Life Sciences Group?

Other companies that are similar to SELLAS Life Sciences Group include Aldeyra Therapeutics, KalVista Pharmaceuticals, Clovis Oncology, Atossa Therapeutics, Werewolf Therapeutics, Vaccitech, Evelo Biosciences, Applied Therapeutics, Basilea Pharmaceutica, Lexicon Pharmaceuticals, Alzamend Neuro, ZIOPHARM Oncology, XBiotech, Mirum Pharmaceuticals and Nanobiotix.

How do I contact SELLAS Life Sciences Group's investor relations team?

SELLAS Life Sciences Group's physical mailing address is 15 WEST 38TH STREET 10TH FLOOR, NEW YORK NY, 10018. The company's listed phone number is (646) 200-5278 and its investor relations email address is [email protected] The official website for SELLAS Life Sciences Group is www.sellaslifesciences.com.